NeuralCipher Research overview
The text below is the source article’s original abstract under a verified reuse license. cc by
Parkinson’s disease (PD) is a progressive neurodegenerative disorder. It shares many pathophysiologic similarities with Type 2 diabetes mellitus (T2DM). Numerous studies have explored the repurposing of antidiabetic medications for their potential neuroprotective effects in PD. There has not been a consolidated review on the biochemical biomarkers that have been evaluated across antidiabetic medications. This review aims to assess the current landscape of biomarker research in evaluating the efficacy of these antidiabetic agents as disease-modifying therapies in PD. We examine the molecular mechanisms targeted by these drugs, the biomarkers used to assess their effects, and the outcomes of clinical trials. The review hopes to identify gaps in current research and enhance the evaluation of antidiabetic medications in PD.
Scientific assessment
Research question
Assess the question within the original study’s scope.
Methods & sample
Check the source article for study design and sample details.
Key findings
An editorially approved findings summary is not yet published for this record.
Limitations
Generalizability, bias and clinical meaning require separate assessment.
Methods, samples and clinical conclusions are not inferred from bibliographic metadata.